310 related articles for article (PubMed ID: 22112546)
1. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
[TBL] [Abstract][Full Text] [Related]
2. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
3. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
4. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
Kapp JA; Honjo K; Kapp LM; Xu Xy; Cozier A; Bucy RP
Int Immunol; 2006 Nov; 18(11):1549-62. PubMed ID: 16966495
[TBL] [Abstract][Full Text] [Related]
5. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
6. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.
Jensen SM; Twitty CG; Maston LD; Antony PA; Lim M; Hu HM; Petrausch U; Restifo NP; Fox BA
J Immunol; 2012 Jul; 189(2):767-76. PubMed ID: 22723522
[TBL] [Abstract][Full Text] [Related]
7. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
8. Antigen, in the presence of TGF-beta, induces up-regulation of FoxP3gfp+ in CD4+ TCR transgenic T cells that mediate linked suppression of CD8+ T cell responses.
Kapp JA; Honjo K; Kapp LM; Goldsmith K; Bucy RP
J Immunol; 2007 Aug; 179(4):2105-14. PubMed ID: 17675469
[TBL] [Abstract][Full Text] [Related]
9. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
11. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
13. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
[TBL] [Abstract][Full Text] [Related]
14. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.
Mehrotra S; Al-Khami AA; Klarquist J; Husain S; Naga O; Eby JM; Murali AK; Lyons GE; Li M; Spivey ND; Norell H; Martins da Palma T; Onicescu G; Diaz-Montero CM; Garrett-Mayer E; Cole DJ; Le Poole IC; Nishimura MI
J Immunol; 2012 Aug; 189(4):1627-38. PubMed ID: 22798675
[TBL] [Abstract][Full Text] [Related]
15. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
16. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
Chen W; Jin W; Hardegen N; Lei KJ; Li L; Marinos N; McGrady G; Wahl SM
J Exp Med; 2003 Dec; 198(12):1875-86. PubMed ID: 14676299
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Intestinal Inflammation With Epicutaneous Immunotherapy Requires TGF-β and IL-10 but Not Foxp3
Chen X; Berin MC; Gillespie VL; Sampson HA; Dunkin D
Front Immunol; 2021; 12():637630. PubMed ID: 33717186
[No Abstract] [Full Text] [Related]
18. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.
Hindley JP; Ferreira C; Jones E; Lauder SN; Ladell K; Wynn KK; Betts GJ; Singh Y; Price DA; Godkin AJ; Dyson J; Gallimore A
Cancer Res; 2011 Feb; 71(3):736-46. PubMed ID: 21156649
[TBL] [Abstract][Full Text] [Related]
19. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo.
Chen Q; Kim YC; Laurence A; Punkosdy GA; Shevach EM
J Immunol; 2011 Jun; 186(11):6329-37. PubMed ID: 21525380
[TBL] [Abstract][Full Text] [Related]
20. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y; Huang R; Zong X; He X; Mo W
BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
